Edition:
United Kingdom

Agios Pharmaceuticals Inc (AGIO.OQ)

AGIO.OQ on NASDAQ Stock Exchange Global Select Market

86.45USD
20 Apr 2018
Change (% chg)

$-1.84 (-2.08%)
Prev Close
$88.29
Open
$87.76
Day's High
$88.20
Day's Low
$86.19
Volume
221,093
Avg. Vol
209,922
52-wk High
$89.26
52-wk Low
$45.20

Select another date:

Mon, Mar 19 2018

BRIEF-Agios Says First Patient Dosed In Lymphoma Study

* AGIOS ANNOUNCES FIRST PATIENT DOSED WITH MAT2A INHIBITOR AG-270 IN PHASE 1 STUDY IN PATIENTS WITH ADVANCED SOLID TUMORS OR LYMPHOMA WITH AN MTAP DELETION Source text for Eikon: Further company coverage:

BRIEF-Agios Reports Qtrly Loss Per Share $1.81

* AGIOS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Agios sizes up funding needs

Jan 19 (IFR) - Agios Pharmaceuticals pivoted from industry conferences to the capital markets, securing US$425m in a follow-on stock sale that meets its funding needs for the year.

BRIEF-Agios prices offering of 7.09 mln shares at $67 per share

* AGIOS ANNOUNCES PRICING OF $475 MILLION PUBLIC OFFERING OF COMMON STOCK

BRIEF-Agios Announces Proposed Offering Of Common Stock

* SAYS IT IS OFFERING TO SELL UP TO $400 MILLION OF ITS COMMON STOCK IN A PUBLIC OFFERING

BRIEF-Agios Outlines Key 2018 Priorities Expanding Clinical And Research Programs To Drive Long Term Value

* AGIOS OUTLINES KEY 2018 PRIORITIES EXPANDING CLINICAL AND RESEARCH PROGRAMS TO DRIVE LONG TERM VALUE

BRIEF-Agios Submits New Drug Application To The FDA For Ivosidenib

* AGIOS SUBMITS NEW DRUG APPLICATION TO THE FDA FOR IVOSIDENIB FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY AML AND AN IDH1 MUTATION

BRIEF-Agios Pharmaceuticals Presents New Safety Data From Study on Leukemia Drug

* PRESENTS NEW SAFETY DATA FROM PHASE 1 EXPANSION STUDY EVALUATING ORAL IVOSIDENIB IN PATIENTS WITH R/R AML AND IDH1 MUTATION

Promising responses seen with Agios leukemia drug in study

Nearly a third of patients with an advanced form of a fast-progressing leukemia who carry a specific genetic mutation experienced a complete or near complete response to an experimental Agios Pharmaceuticals drug, according to data from an early stage trial released on Monday.

Promising responses seen with Agios leukemia drug in study

Dec 11 Nearly a third of patients with an advanced form of a fast-progressing leukemia who carry a specific genetic mutation experienced a complete or near complete response to an experimental Agios Pharmaceuticals drug, according to data from an early stage trial released on Monday.

Select another date: